Chávez PI, González FMC, Aguilar RM, Cardoso GE

Language: Spanish
References: 14
Page: 1744-1751
PDF size: 151.97 Kb.

ABSTRACT

Introduction: rubeosis of iridis is the most frequent and precocious of many vascular diseases of the posterior segment complication. Neovascularization management is divided into two aspects: the treatment of the subjacent disease responsible for rubeosis and the treatment of intraocular pressure increase, if present.
Objective: to demonstrate the effectiveness of a therapeutic option given by poor results of usual treatments for these complications.
Clinical case: a patient with rubeosis of iridis associated with proliferative diabetic retinopathy is presented; the patient was assessed through the best corrected visual acuity examination, biomiscroscopy of the anterior and posterior segment, indirect ophthalmoscopy, tonometry and gonioscopy. Classification of rubeosis of iridis was performed in degrees according to the number of quadrants affected by neovessels, grade I to grade IV, and grade V, when hyphema was presented, besides neovessels in all quadrants. The ophthalmoscopic examination and the posterior segment biomicroscopy were disallowed by total opacity of the lens which prevented details of the fundus. The anterior segment biomicroscopy ranked patient in grade V, presenting cilioconjunctival injection, and corneal edema, hyphema of 3 mm coagulated, fresh blood and neovessel in all quadrants.
Conclusions: the patient was treated with intravitreal triamcinolone injection with symptoms and signs improvement.

REFERENCES

1. Verdaguer J, Zanolli M, Sepúlveda G, García_de_los_Ríos M, Domínguez A. Historia natural de la Retinopatía Diabética en un estudio a largo plazo en pacientes con diabetes tipo I. Rev Médica Chile. 2009;137(9):1145-52.

2. Esteffan Karim C, Navea C, Ageno Yannina E. Retinopatía Diabética. Rev Ciencia Salud. 2008;12(1):49-54.

3. Kanski J. Oftalmología clínica. 5ed. España: Editorial Eselvler; 2005.

4. Rey Estévez BN, Varela Gener E, Alba Carcasés Y, Bibianes Maché MC, García Galí M. Glaucoma y retinopatía en pacientes con diabetes mellitas. MEDISAN [Internet]. 2007 [citado 15 Abr 2011];11(2):[aprox. 9 p.]. Disponible en: http//bvs.sld.cu/revistas/san/vol11_2_07/san07207.htm

5. Spaide FR. Las inyecciones intravítrea de corticoides sugeridas para el tratamiento de diversas enfermedades retinianas. Ophthalmology times. 2005;9(6):12-4.

6. Machemer R, Sugita G. Treatment of intraocular proliferations withintravítrea steroids. Trans Am Ophtahlmol Soc. 2004;77:171-80.

7. Jonas JB, Hayler JK, Söfker A, Panda Jonas S. Regression of neovascular iris vessels by intravitreal injection of crystalline cortisone. J Glaucoma.2001;10:284-7.

8. Yong Tao, Jonas JB. Intravitreal Triamcinolone. Ophthalmological. 2011;225(1):1-20.

9. Martínez Carpio PA, Bonafonte Márquez E, Heredia García CD, Bonafonte Royo S. Eficacia y seguridad de la inyección intravítrea de bevacizumab en el tratamiento del glaucoma neovascular: revisión sistemática. Arch Soc Esp Oftalmol [Internet]. 2008 [citado 15 Abr 2011];83:[aprox. 10 p]. Disponible en: http://scielo.isciii.es/scielo.php?pid=S0365

10. Jermak CM, Dellacroce JT, Heffez J, Peyman GA. Triamcinolone acetonide in ocular therapeutics. Surv Ophthalmol. 2007;52:503-22.

11. Collignon NJ, Crommen J, Collignon-Brach J, Rakic JM. Low dose intravitreal triamcinolone acetonide in the treatment of neovasular glaucoma. Bull Soc Belge Ophtalmol. 2005;298:5-10.

12. Gómez Ulla F, Basauri E, Arias L, Martínez Sanz F. Manejo de las inyecciones intravítreas. Arch Soc Esp Oftalmol [Internet]. 2009 [citado 15 Abr 2011];84(8):[aprox. 9 p]. Disponible en: http://scielo.isciii.es/scielo.php?pid=S0365

13. Rojas Rondón I, Rivas Canino MC, Eguias Martínez F, Rodríguez Masó S, D'Castro P, Ramos López M. Uso de la triamcinolona subtenoniana en pacientes con rubeosis del iris. Rev Cubana Oftalmol. 2008;21(2):24-34.

14. Zacks DN, Johnson Mark WM. Combined Intravitreal Injection of Triamcinolone Acetonide and Panretinal Photocoagulation for Concomitant Diabetic Macular Edema and Proliferative Diabetic Retinopathy. Ohiolink. 2005; 25 (2): 135-40.